Goldman Sachs takes a steadier view on Intuitive Surgical as the market punishes the sector leader

Intuitive Surgical has remained one of healthcare’s most visibly punished large-cap names in 2026, according to a market report, with the stock down about 28% for the year even as revenue continues to climb. The divergence between a falling share price and still-growing sales has become a central theme for investors tracking the company, the maker of the da Vinci surgical robot system that is used in thousands of minimally invasive procedures worldwide.

Against that backdrop, the report says Goldman Sachs is delivering a call on Intuitive Surgical that “goes against the grain.” In other words, while many investors have been reacting to concerns reflected in the stock’s drop, the bank’s stance suggests it sees reasons to be less bearish than the market is currently pricing in.

The da Vinci platform sits at the center of Intuitive Surgical’s business model. Hospitals buy access to the robotic system and then incur recurring spending on procedure-related consumables and service, which tends to make the company’s revenue path closely tied to how frequently the robots are used and how quickly new installations are adopted.

The market’s pushback on Intuitive Surgical, as framed by the report, appears to be driven by expectations rather than by the company’s ability to grow revenue. Even with sales heading higher, the stock has fallen, suggesting that investors are likely trying to answer harder questions such as how quickly demand will translate into procedure growth, what pricing and mix will look like, and how competitive dynamics could affect margins and long-term growth rates.

Goldman Sachs, as described in the report, is making the case that investors may be underweighting those positives relative to the stock’s current valuation and recent negative momentum. For a large-cap like Intuitive Surgical, that kind of positioning can matter because the market often uses big moves in expectations to reprice both the company’s near-term outlook and the durability of its installed base economics.

Still, the report does not provide granular details in the excerpted material here, such as the specific rating, price target, or the precise set of operating assumptions behind the bank’s view. It also does not specify whether Goldman’s perspective is based on changes in procedure volumes, installation growth, reimbursement trends, competitive factors, or any particular regulatory or technology milestone.

For investors watching the broader medical robotics and surgical equipment space, Intuitive Surgical is often treated as a bellwether because it is the scale leader and because its results can influence how the market thinks about adoption of robot-assisted surgery. When shares slide while revenues rise, the implication is typically that investors are moving from rewarding growth at any price to demanding clearer evidence on earnings power, utilization, and conversion of installed systems into higher-frequency use.

What to watch next is whether Intuitive Surgical’s next set of quarterly updates and forward guidance can narrow the gap between revenue growth and market expectations that appear to be weighing on the stock. The immediate question is not only whether the business continues growing, but whether it delivers the kind of operating trajectory that would justify the share-price recovery after a year of steep declines, as the report frames it.